company background image

Wanbury BSE:524212 Stock Report

Last Price


Market Cap







16 Aug, 2022


Company Financials
524212 fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance2/6
Financial Health1/6

524212 Stock Overview

Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India.

Wanbury Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Wanbury
Historical stock prices
Current Share Price₹64.05
52 Week High₹111.75
52 Week Low₹55.55
1 Month Change-2.21%
3 Month Change-6.29%
1 Year Change-21.22%
3 Year Change407.13%
5 Year Change71.95%
Change since IPO-65.63%

Recent News & Updates

Shareholder Returns

524212IN PharmaceuticalsIN Market

Return vs Industry: 524212 underperformed the Indian Pharmaceuticals industry which returned -12% over the past year.

Return vs Market: 524212 underperformed the Indian Market which returned 8.3% over the past year.

Price Volatility

Is 524212's price volatile compared to industry and market?
524212 volatility
524212 Average Weekly Movement5.8%
Pharmaceuticals Industry Average Movement5.9%
Market Average Movement6.4%
10% most volatile stocks in IN Market9.0%
10% least volatile stocks in IN Market4.1%

Stable Share Price: 524212 is not significantly more volatile than the rest of Indian stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: 524212's weekly volatility (6%) has been stable over the past year.

About the Company


Wanbury Limited manufactures and sells formulations and active pharmaceutical ingredients (API) in India. The company offers formulations for gynecology, orthopedics, heamatinics, anti-diabetic, nutraceuticals, gastro intestinal, stroke surgery, antibiotics, cough and cold solutions, anti-inflammatory, analgesics, and general practitioner purposes approximately under 70 brands. It also provides API products for anti-diabetic, anti-analgesic, anti-depressant, anti-histaminic, anti-inflammatory, anti-arthritis, anti-thrombotic, anti-epileptic, and anti-hypertensive therapeutic areas.

Wanbury Fundamentals Summary

How do Wanbury's earnings and revenue compare to its market cap?
524212 fundamental statistics
Market Cap₹2.09b
Earnings (TTM)₹750.90m
Revenue (TTM)₹5.00b


P/E Ratio


P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
524212 income statement (TTM)
Cost of Revenue₹3.00b
Gross Profit₹2.00b
Other Expenses₹1.25b

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)22.97
Gross Margin39.99%
Net Profit Margin15.01%
Debt/Equity Ratio-314.3%

How did 524212 perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.


Is 524212 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score


Valuation Score 4/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 524212?

Other financial metrics that can be useful for relative valuation.

524212 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.5x
Enterprise Value/EBITDA8.9x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does 524212's PE Ratio compare to its peers?

524212 PE Ratio vs Peers
The above table shows the PE ratio for 524212 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average20x
JSLL Jeena Sikho Lifecare
500009 Ambalal Sarabhai Enterprises
PAR Par Drugs and Chemicals
531726 Panchsheel Organics
524212 Wanbury

Price-To-Earnings vs Peers: 524212 is good value based on its Price-To-Earnings Ratio (2.8x) compared to the peer average (20x).

Price to Earnings Ratio vs Industry

How does 524212's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

Price-To-Earnings vs Industry: 524212 is good value based on its Price-To-Earnings Ratio (2.8x) compared to the Indian Pharmaceuticals industry average (22.6x)

Price to Earnings Ratio vs Fair Ratio

What is 524212's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

524212 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio2.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 524212's Price-To-Earnings Fair Ratio for valuation analysis.

Share Price vs Fair Value

What is the Fair Price of 524212 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 524212 (₹64.05) is trading below our estimate of fair value (₹198.74)

Significantly Below Fair Value: 524212 is trading below fair value by more than 20%.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Future Growth

How is Wanbury forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score


Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Wanbury has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Discover growth companies

  • Examine whether Wanbury is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
  • Wanbury competitive advantages and company strategy can generally be found in its financial reports archived here.

Past Performance

How has Wanbury performed over the past 5 years?

Past Performance Score


Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: 524212 has a large one-off gain of ₹763.7M impacting its June 30 2022 financial results.

Growing Profit Margin: 524212 became profitable in the past.

Past Earnings Growth Analysis

Earnings Trend: 524212's earnings have grown significantly by 52.4% per year over the past 5 years.

Accelerating Growth: 524212 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 524212 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.3%).

Return on Equity

High ROE: 524212's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.

Discover strong past performing companies

Financial Health

How is Wanbury's financial position?

Financial Health Score


Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: 524212 has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: 524212 has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.

Debt to Equity History and Analysis

Debt Level: 524212 has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: 524212's has negative shareholder equity, so we do not need to check if its debt has reduced over time.

Debt Coverage: 524212's debt is well covered by operating cash flow (51%).

Interest Coverage: 524212's interest payments on its debt are not well covered by EBIT (0.9x coverage).

Balance Sheet

Discover healthy companies


What is Wanbury current dividend yield, its reliability and sustainability?

Dividend Score


Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate 524212's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 524212's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 524212's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 524212's dividend payments have been increasing.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as 524212 has not reported any payouts.

Discover strong dividend paying companies


How experienced are the management team and are they aligned to shareholders interests?


Average management tenure


Wanbury has no CEO, or we have no data on them.

Leadership Team

Experienced Management: 524212's management team is seasoned and experienced (6.3 years average tenure).

Board Members

Experienced Board: 524212's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Who are the major shareholders and have insiders been buying or selling?

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Company Information

Wanbury Limited's employee growth, exchange listings and data sources

Key Information

  • Name: Wanbury Limited
  • Ticker: 524212
  • Exchange: BSE
  • Founded: 1988
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: ₹2.094b
  • Shares outstanding: 32.70m
  • Website:

Number of Employees


  • Wanbury Limited
  • BSEL Tech Park, B-Wing
  • 10th Floor
  • Navi Mumbai
  • Maharashtra
  • 400703
  • India


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/08/16 00:00
End of Day Share Price2022/08/16 00:00
Annual Earnings2022/03/31

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.